Phase 1 Dose Finding Study of Belinostat Plus Cyclophosphamide/Vincristine/Doxorubicin/Prednisone (CHOP) Regimen (BelCHOP) for Treatment of Patients With Peripheral T-cell Lymphoma(PTCL)

Trial Profile

Phase 1 Dose Finding Study of Belinostat Plus Cyclophosphamide/Vincristine/Doxorubicin/Prednisone (CHOP) Regimen (BelCHOP) for Treatment of Patients With Peripheral T-cell Lymphoma(PTCL)

Completed
Phase of Trial: Phase I

Latest Information Update: 21 Apr 2016

At a glance

  • Drugs Belinostat (Primary) ; Cyclophosphamide; Doxorubicin; Prednisone; Vincristine
  • Indications Peripheral T-cell lymphoma
  • Focus Adverse reactions
  • Sponsors Spectrum Pharmaceuticals
  • Most Recent Events

    • 08 Dec 2015 Results presented at the 57th Annual Meeting and Exposition of the American Society of Hematology.
    • 06 Dec 2015 Results were published in a Spectrum Pharmaceuticals and Onxeo media release.
    • 04 Dec 2015 Planned End Date changed from 1 Dec 2015 to 1 Mar 2016 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top